

August 19, 2024

**BSE Limited**

Corporate Relationship Department  
Phiroze Jeejeebhoy Towers,  
Dalal Street, Fort,  
Mumbai – 400 001.

**National Stock Exchange of India Limited**

Listing Department  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East),  
Mumbai – 400 051.

Scrip code: 512529

Symbol: SEQUENT

Dear Sir/ Madam,

**Subject: Press Release - Sequent Scientific Limited Receives Prequalification Approval from World Health Organization (WHO) for Albendazole API**

Pursuant to Regulation 30 read with Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the Press Release titled “SeQuent Scientific Limited receives Prequalification Approval from World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API)”.

Thanking you,

Yours faithfully,  
For **Sequent Scientific Limited**

**Phillip Trott**  
**Company Secretary & Compliance Officer**

Encl.: A/a

SeQuent Scientific Limited

**Registered Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra, India

**Tel No.:** +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)

## **Sequent Scientific Limited Receives WHO Prequalification Approval for Albendazole API**

Mumbai, 19th August 2024 – Sequent Scientific Limited, a leading Indian pharmaceutical company, proudly announces its receipt of prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This is in partnership with **Mepro Pharmaceuticals Private Limited**, who have successfully developed and commercialised the Albendazole Chewable formulation from its WHO PQ approved plant, using our API. Mepro's Chewable formulation is the first global approval of its kind by the WHO PQ.

Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle-income countries. The WHO prequalification recognizes Sequent Scientific Limited's commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality.

"The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale," said Rajaram Narayanan, MD & CEO of Sequent Scientific Limited.

### **About Sequent Scientific Limited:**

Sequent Scientific Limited is India's leading animal health company with a consolidated turnover of ₹ 13.69 billion for FY24. Sequent Scientific Limited, through its subsidiaries, has operations in over 90 countries with 7 manufacturing facilities, serving consumers worldwide.

### **About Mepro:**

Mepro Pharmaceuticals is a privately-owned pharmaceutical company with over 4 decades of experience in delivering quality healthcare to highly regulated markets including UK/EU/Canada, Australia amongst others. Headquartered in Mumbai, India, they specialize in the development and manufacturing of niche and technically complex pharmaceutical products across its 4 manufacturing facilities.

SeQuent Scientific Limited

**Registered Office:** 301, 3<sup>rd</sup> Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra, India

**Tel No.:** +91-22-4111-4777 | **CIN:** L99999MH1985PLC036685

**Website:** <http://www.sequent.in> | **Email Id:** [investorrelations@sequent.in](mailto:investorrelations@sequent.in)